ELANNYSEPharmaceutical PreparationsFiscal year ends December 31

Elanco Animal Health Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$23.49−0.06 (-0.25%)

Close on Oct 19, 2026

Market cap: $11.88B
P/E (TTM): –
Dividend yield: –

Elanco Animal Health Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	4,715	4,439	4,417	4,411	4,764	3,271	3,071	3,067	2,889	2,914
Cost of Revenue	2,122	2,003	1,931	1,913	2,132	1,667	1,470	1,574	1,494	1,409
Gross Profit	2,593	2,436	2,486	2,498	2,632	1,604	1,601	1,493	1,395	1,505
Research & Development	368	344	327	321	369	329	270	247	252	266
Selling, General & Admin	1,430	1,314	1,285	1,265	1,403	997	760	735	780	785
Advertising Expenses	314	236	207	201	248	–	–	–	–	–
Total Costs & Expenses	–	3,951	5,612	4,483	5,335	3,948	2,993	2,953	3,122	2,936
Interest Expense	–	–	277	241	236	150	79	30	0	0
Interest & Investment Income	43	31	4.00	–	–	–	–	–	–	–
Other Non-Operating Income	–	–	-75	-32	-5.00	178	-28	-41	0.10	2.80
Merger & Restructuring Charges	156	44	0	-7.00	110	623	186	129	375	308
Asset Impairment Charges	71	81	32	0	0	0	16	82	111	98
Gain (Loss) on Sale of Assets	0	640	0	0	0	4.00	0	0.80	20	0
Legal Settlements	–	–	–	–	-10	–	–	–	–	–
Pretax Income	-224	488	-1,195	-72	-571	-677	78	114	-233	-22
Income Tax Expense	8.00	150	36	6.00	-88	-103	10	28	78	26
Net Income	-232	338	-1,231	-78	-483	-574	68	87	-311	-48
EPS (Basic)(per share)	-0.47	0.68	-2.50	-0.16	-0.99	-1.30	0.18	0.28	-1.06	-0.16
EPS (Diluted)(per share)	-0.47	0.68	-2.50	-0.16	-0.99	-1.30	0.18	0.28	-1.06	-0.16
Shares Outstanding (Basic, Weighted)(shares)	496	494	492	488	487	441	369	314	293	293
Shares Outstanding (Diluted, Weighted)(shares)	496	497	492	488	487	441	370	314	293	293

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 55.4%
Operating margin: –
Net margin: -4.0%
Return on equity, FY2025: -3.7%

Financial strength

Current ratio: 2.05
Debt to equity: 0.59
Debt to assets: 28.9%
Cash to current liabilities: 28.6%

Valuation

P/E ratio: –
Price to sales: 2.37
Price to book: 1.80
Dividend yield: –